Plasvacc
24/7 HELP HOTLINE WITHIN AUSTRALIA 1800 752 762
  • Home
  • Products
    • Products overview
    • Equiplas
    • Equiplas-R
    • Equiplas-E
    • Caniplas
    • Caniplas E
    • CaniPRBC
    • Camelplas
    • Diagnostic Kits
  • How to buy
  • Technology
    • Plasma Therapy
    • Collection process
    • Thawing instructions
    • Product usage
    • Storage
  • Research
    • Scientific papers
    • White papers
    • Background papers
  • About
    • Company overview
    • Animal ethics
    • Plasvacc team
    • Regional commitment
  • Blog
  • Contact

Plasvacc Expands to UK, Acquiring Veterinary Immunogenics

Home» Plasvacc News » Plasvacc Expands to UK, Acquiring Veterinary Immunogenics

Plasvacc Expands to UK, Acquiring Veterinary Immunogenics

PENRITH, UNITED KINGDOM — Plasvacc UK Ltd. is pleased to announce its entry into the United Kingdom through its acquisition of Veterinary Immunogenics Inc.

Effective immediately, Plasvacc will undertake the day-to-day management of Veterinary Immunogenics under the oversight of site manager Fergus Macarthur.

Incorporated in 1992, Veterinary Immunogenics has been producing and supplying hyperimmunised equine plasma products for veterinary use for over 30 years under the Hypermune and Hypermune RE brand names. With an emphasis on customer care, Veterinary Immunogenics has specialised in providing high-quality plasma products to veterinarians, breeders and trainers in the UK, Ireland & European countries.

“With an impressive track record spanning three decades, we’re grateful for the tireless efforts of Dr. Thomas Barr BVMS MRCVS and Eileen Barr to advance plasma-based equine veterinary medicine in the United Kingdom,” said Andrew Macarthur, CEO of Plasvacc UK Ltd.

“A sure sign that Veterinary Immunogenics was a great fit for the Plasvacc Group of Companies was their unwavering commitment to product quality and exceptional customer service that closely mirrors our own. We’re very pleased to be adding the first-rate Veterinary Immunogenics employees to the Plasvacc Team,” continued Macarthur.

Aside from the transition in management, the Veterinary Immunogenics product line and day-to-day operations will remain unchanged.

About Plasvacc’s International Companies

Founded in 1996 as Plasvacc Pty. Ltd. in Australia and expanded through Plasvacc USA Inc. in 2005, Plasvacc’s global companies manufacture and distribute high-quality hyperimmunised blood plasma products used to supplement the immune response system in animals. Firmly committed to animal ethics, Plasvacc prides itself in delivering the highest quality product possible while delivering unmatched customer service and technical support.

Comments are closed.

FoalsBestStart.com
Want the best for your dog?
See more products

About us

Plasvacc manufactures and distributes high quality hyperimmunised blood plasma products used to supplement the immune response system in animals. Plasma therapy shortens the course of treatments, reduces hospitalisation periods and lessens the quantity of drugs required to treat a variety of medical conditions.

SIGN UP FOR OUR MAILING LIST





    Contact us

    • Telephone: +61 7 5463 7600
    • Technical Support: 1-800-PLASMA | 1-800-752762
    • plasmail@plasvacc.com
    • Contact Us
      • ✉
      • 
      • 
      • 
    • Products
      • Equiplas
      • Equiplas-R
      • Equiplas-E
      • Caniplas
      • Caniplas E
      • CaniPRBC
      • Camelplas
      • Diagnostic Kits
    • How to buy
      • Wholesalers
    • Company overview
      • Plasvacc team
      • Animal ethics
      • Regional commitment
    • Research
      • Scientific papers
      • Background papers
      • White papers
    • Technology
      • Plasma therapy
      • Collection process
      • Thawing Instructions
      • Product usage
      • Storage

    (c) 2012 Plasvacc | All Rights Reserved | privacy policy

    Manage Cookie Consent
    We use cookies to optimise our website and our service.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    Preferences
    {title} {title} {title}